MSK's Next-Generation Sequence Testing

MSK's Next-Generation Sequence Testing


Taking a closer look.  Making a bigger impact.

MSK-IMPACT® is a targeted DNA sequencing test available to cancer patients. It can detect mutations and other critical changes in the most important cancer genes using DNA from tumor tissue and matched healthy cells.

MSK-ACCESSSM is a “liquid biopsy” test that can detect many of these same mutations with ultra-high sensitivity in cell-free DNA collected from blood plasma.

Commercial Application

Both tests are used in precision diagnosis as well as for matching patients to available therapies or clinical trials that will benefit them most.

Product Details 

To learn more about distinguishing product features, validation methods, and the underlying value of these two tests, see here.

Licensing Opportunities

For licensing information, please contact:

Stage of Development

Ready to use